New technology advisory board at Silence Therapeutics

Jörg Vollmer, a veteran biotechnology executive, is to lead a new technology advisory board at Silence Therapeutics Plc, which is developing therapeutics based on ribonucleic acid (RNA) for cancer and other diseases.